In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Alnylam Pharmaceuticals ALNY with an Overweight rating and $35.00 price target.
In the report, Morgan Stanley noted, “We view Alnylam as the leader in RNAi drug development. The components of this technology platform (i.e. drug delivery, drug composition, target selection) have progressed to the point where we have high confidence in the ability to move from a science-based company to a commercial one.”
Alnylam Pharmaceuticals closed on Monday at $30.87.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.